Hedera Dx is on a mission to make liquid biopsies globally accessible by enabling hospital laboratories to run CE‑IVDR compliant, clinically actionable circulating tumor DNA (ctDNA) testing in-house. The company streamlines tumor profiling and cancer treatment monitoring to expand personalized therapy options for more patients.

Hedera Dx offers Hedera Prime, a registered CE‑IVD medical device software, together with the Hedera Profiling 2 ctDNA pan‑cancer assay. The integrated solution simplifies NGS-based liquid biopsy workflows, reporting, and regulatory compliance. Hedera Dx is also building clinical evidence through studies such as EMPATHY NSCLC to validate real-world utility.

Founded in 2021 and co‑led by experienced diagnostics and oncology leaders, Hedera Dx is a fast‑growing startup with teams across Europe and headquarters in Epalinges, Switzerland.